Article

Treatment of Patients with Schizophrenia and Substance Abuse Disorders

Department of Psychiatry, School of Medicine, Harbor-UCLA Medical Center and University of California at Los Angeles, Los Angeles, CA, USA.
Current Pharmaceutical Design (Impact Factor: 3.29). 02/2004; 10(18):2249-61. DOI: 10.1097/01.adt.0000186367.15415.0d
Source: PubMed

ABSTRACT Approximately half of patients with schizophrenia have a lifetime diagnosis of substance abuse disorders. These dual diagnosis patients are more likely to have poorer outcomes, including more severe psychiatric symptoms with increased hospitalizations, higher utilization of services and frequent homelessness. Assessment and treatment of dually diagnosed patients has evolved over the last twenty years. To date, the strongest evidence for effective management of dual diagnosis patients has been utilization of integrated treatment services, which combines both mental health and substance abuse treatments concurrently. Strategies commonly used include a combination of pharmacological treatment, intensive case management, motivational interviewing, individual and group psychotherapy, and family participation. This chapter summarizes the treatment options available for this population.

0 Followers
 · 
115 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: Treatment of schizophrenia in patients with comorbid substance use (alcohol/illicit drug use, abuse or dependence) presents challenges for public health systems. Substance use in people with schizophrenia is up to four times greater than the general population and is associated with medication nonadherence and poor outcomes. Therefore, continuous antipsychotic treatment in this population may pose more of a challenge than for those with schizophrenia alone. Many clinical trials and treatment recommendations in schizophrenia do not take into consideration substance use as people with comorbid substance use have typically been excluded from most antipsychotic trials. Nonetheless, antipsychotic treatment appears to be as efficacious in this population, although treatment discontinuation remains high. The objective of this review was to highlight the importance and utility of considering long-acting injectable antipsychotics for patients with schizophrenia and comorbid substance use. METHODS: We did a literature search using PubMed with key words schizophrenia and substance use/abuse/dependence, nonadherence, antipsychotics, long acting injectables, relapse, and psychosocial interventions. We limited our search to human studies published in English and 4,971 articles were identified. We focused on clinical trials, case reports, case series, reviews and meta-analyses resulting in 125 articles from 1975-2011. RESULTS: Our review suggests the potential role of long-acting injectables for people with comorbid substance use and schizophrenia in leading to improvements in psychopathology, relapse prevention, fewer rehospitalizations, and better outcomes. CONCLUSIONS: While more research is needed, long-acting antipsychotics should be considered an important option in the management of people with schizophrenia and comorbid substance use.
    Journal of Dual Diagnosis 01/2012; 8(1):50-61. DOI:10.1080/15504263.2012.647345 · 0.80 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The PERSEO study (psychiatric emergency study and epidemiology) is a naturalistic, observational clinical survey in Italian acute hospital psychiatric units, called SPDCs (Servizio Psichiatrico Diagnosi e Cura; in English, the psychiatric service for diagnosis and management). The aims of this paper are: (i) to describe the epidemiological and clinical characteristics of patients, including sociodemographic features, risk factors, life habits and psychiatric diagnoses; and (ii) to assess the clinical management, subjective wellbeing and attitudes toward medications. A total of 62 SPDCs distributed throughout Italy participated in the study and 2521 patients were enrolled over the 5-month study period. Almost half of patients (46%) showed an aggressive behaviour at admission to ward, but they engaged more commonly in verbal aggression (38%), than in aggression toward other people (20%). A total of 78% of patients had a psychiatric diagnosis at admission, most frequently schizophrenia (36%), followed by depression (16%) and personality disorders (14%), and no relevant changes in the diagnoses pattern were observed during hospital stay. Benzodiazepines were the most commonly prescribed drugs, regardless of diagnosis, at all time points. Overall, up to 83% of patients were treated with neuroleptic drugs and up to 27% received more than one neuroleptic either during hospital stay or at discharge. Atypical and conventional antipsychotics were equally prescribed for schizophrenia (59 vs 65% during stay and 59 vs 60% at discharge), while atypical drugs were preferred in schizoaffective psychoses (72 vs 49% during stay and 70 vs 46% at discharge) and depression (41 vs 32% during stay and 44 vs 25% at discharge). Atypical neuroleptics were slightly preferred to conventional ones at hospital discharge (52 vs 44%). Polypharmacy was in general widely used. Patient attitudes toward medications were on average positive and self-reported compliance increased during hospital stay. Results confirm the widespread use of antipsychotics and the increasing trend in atypical drugs prescription, in both psychiatric in- and outpatients.
    Annals of General Psychiatry 02/2007; 6:29. DOI:10.1186/1744-859X-6-29 · 1.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fragestellung Es ist wenig darüber bekannt, in welchem Ausmaß evidenzbasierte Psychotherapie in der Routineversorgung zur Behandlung von Menschen mit Schizophrenie in Deutschland angewandt wird. Methode Es wird zunächst ein Literaturüberblick zur Wirksamkeit verschiedener psychotherapeutischer Verfahren im Rahmen der Behandlung schizophrener Erkrankungen gegeben. Dann wird anhand einer systematischen Literaturrecherche und der Analyse mehrerer Datensätze eine Bestandsaufnahme des Implementierungsgrades von Psychotherapie in der Behandlungspraxis schizophrener Störungen vorgenommen. ErgebnisseDie „Efficacy“ kognitiver Verhaltenstherapie in der Behandlung schizophrener Störungen kann als gut belegt gelten. Die wenigen vorliegenden Daten zum Implementierungsgrad lassen auf eine erhebliche Evidenzlücke in der Behandlungspraxis schließen. Diskussion Implementierungshemmnisse werden benannt und diskutiert. Forschungsbedarf besteht v.a. hinsichtlich versorgungsepidemiologischer Daten und langfristig angelegter „Effectiveness-Studien“. Background Little is known about the degree of implementation of evidence-based psychotherapy in routine care of people with schizophrenia in Germany. MethodFirst, results of studies on the efficacy of psychotherapy in the treatment of schizophrenia are summarised. Second, the degree of implementation of psychotherapeutic practices in the routine care of schizophrenics is assessed through a systematic literature search and analyses of several data sets. Results There is substantial evidence for the efficacy of cognitive-behavioural interventions in the treatment of schizophrenia. The paucity of data on the degree of implementation suggests a wide gap between evidence and practice. Conclusions Barriers to implementation are outlined and discussed. There is a need for more studies on epidemiological and long-term effectiveness of health care.
    Der Nervenarzt 11/2006; 77(11):1301-1309. DOI:10.1007/s00115-006-2102-2 · 0.86 Impact Factor

Preview

Download
1 Download
Available from